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Abstract
Background: Transactive response DNA-binding protein 43 (TDP-43) is the pathological protein found in
frontotemporal lobar degeneration with ubiquitin positive inclusions and in amyotrophic lateral sclerosis. In
diseased tissue, TDP-43 translocates from its physiological nuclear location into the cytoplasm, where it
accumulates. Additionally, C-terminal fragments of TDP-43 accumulate in affected brain regions and are sufficient
to cause TDP-43 mislocalization and cytoplasmic accumulation in vitro. TDP-43 also accumulates in 30% of
Alzheimer disease (AD) cases, a finding that has been highly reproducible. The role of TDP-43 in AD and its relation
with Ab and tau pathology, the two neuropathological hallmarks of AD, remains to be elucidated.
Results: Here we show that levels of TDP-43 and its ~35 kDa C-terminal fragment are significantly increased in the
3×Tg-AD mice, an animal model of AD that develops an age-dependent cognitive decline linked to the
accumulation of Ab and tau. We also report that the levels of TDP-43 and its C-terminal fragment correlate with
the levels of soluble Ab oligomers, which play a key role in AD pathogenesis. Notably, genetically reducing Ab42
production restores the levels of TDP-43 and its ~35 kDa C-terminal fragment to control levels.
Conclusions: These data suggest a possible relation between Ab oligomers and TDP-43.
Background
Alzheimer disease (AD) is the most common cause of
dementia among the elderly [1]. Clinical symptoms
include memory loss and impairments in other domains
that interfere with mood, reason, judgment, and lan-
guage [2-4]. Two hallmark neuropathological lesions of
AD include the aberrant accumulation of the amyloid-b
peptide (Ab) and neurofibrillary tangles (NFTs) [5].
Other prominent changes include intraneuronal Ab
accumulation, mitochondrial dysfunction, oxidative
damage, and changes in the protein quality system [6-9].
Ab is the primary protein component of amyloid pla-
ques and originates via proteolysis from the amyloid
precursor protein [10,11]. Ab has been the central focal
point of AD research for more than a decade and is
generally considered the upstream causative factor for
AD [12]. The strongest evidence for this position is
derived from molecular genetic studies of the three
genes (amyloid precursor protein, presenilin 1, and pre-
senilin 2) that underlie familial AD cases, as they all
modulate some aspect of Ab metabolism, increasing the
propensity of Ab to aggregate [13-16]. Indeed, Ab is an
aggregation-prone peptide, and it exists in different
forms such as monomers, oligomers, and fibrils [17,18].
In the past few years, in vitro and in vivo studies have
shown soluble Ab oligomers to be the major neurotoxic
species for neurons [19].
The major component of NFTs is the microtubule-
associated protein, tau [20-23]. In its normal state, tau is
a soluble protein whose function is to promote microtu-
bule assembly and stabilization. Pathological tau protein,
by contrast, exhibits altered solubility properties, forms
filamentous structures, and is abnormally phosphory-
lated at specific residues [20-23]. Recent evidence indi-
cates that the accumulation of soluble, phosphorylated
tau may be more toxic than NFTs [24-27].
Transactive response DNA-binding protein 43 (TDP-
43) is a nuclear protein involved in exon skipping and
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approximate molecular weight of ~44 kDa. Recently,
TDP-43 has been found to be the main protein that
accumulates in frontotemporal lobar degeneration with
ubiquitin positive inclusions (FTLD-U) and in amyo-
trophic lateral sclerosis (ALS) [29]. Pathological TDP-43
is mislocalized from the nucleus to the cytoplasm where
it accumulates [29]. Additionally, TDP-43 C-terminal
fragments have been isolated from affected brain regions
[29,30], and their expression in vitro is sufficient to
cause TDP-43 mislocalization [31-33], suggesting that
t h e s ef r a g m e n t sm a yp l a yar o l ei nt h ed i s e a s e
pathogenesis.
In addition to ALS and FTLD-U, TDP-43 positive
inclusions are present in Parkinson disease, dementia
with Lewy bodies, and in 30% of AD cases [34-37]. The
specific role of TDP-43 in AD has not been identified
yet; specifically, it is not clear whether there is a link
between TDP-43, Ab and tau pathology. In this study,
we address the relation between Ab, tau and TDP-43 in
the 3×Tg-AD mice, an animal model of AD that devel-
ops Ab and tau pathology, with a temporal- and regio-
nal-specific profile that closely mimics their
development in the human AD brain [38].
Results
The accumulation of TDP-43 has been linked to FTLD-
U and ALS [29]. TDP-43 also accumulates in Parkin-
son’s disease, dementia with Lewy bodies, and in 30% of
AD cases [34-37,39]. In AD brains, TDP-43 seems to
prevalently accumulate in the brain areas more suscepti-
ble to Ab and tau pathology such as hippocampus,
amygdala, and in selected cortical regions [40]. However,
the relation between TDP-43, Ab and tau is not known.
To investigate the link between Ab, tau and TDP-43, we
first measured the steady-state levels of TDP-43 and its
C-terminal fragments in the low salt fraction (see mate-
rial and methods) of proteins extracted from in 2-, 6-,
and 12-month-old 3×Tg-AD and NonTg mice (n = 6/
genotype/time-point). We found that in the brains of 2-
month-old mice, the steady-state levels of TDP-43 and
the ~35 kDa C-terminal fragment (herein referred to as
TDP-35), which can be detected by overexposing the
blots, were similar between 3×Tg-AD and age- and gen-
der-matched non transgenic (NonTg) mice (Figure 1A-
B). In contrast, the brains of 6-month-old 3×Tg-AD
mice had significantly higher levels of TDP-43 and
TDP-35 than the age- and gender-matched NonTg mice
(Figure 1C-D). TDP-43 and TDP-35 levels were again
similar between 3×Tg-AD and NonTg mice at 12
months of age (Figure 1E-F). The higher levels of TDP-
43 and TDP-35 in 6-month-old 3×Tg-AD mice coin-
cided with the onset of Ab and tau pathology [38,41].
The difference in TDP-43 levels between 3×Tg-AD and
N o n T gm i c ea t6m o n t h so fa g em i g h tb ed u et oa
decrease in TDP-43 levels in the brains of 6-month-old
3×Tg-AD mice or to an increase in TDP-43 levels in
6-month-old NonTg mice. To discriminate between
these two possibilities, protein extracted from 2-, 6-, and
1 2 - m o n t h - o l dN o n T gm i c ew e r er u no nt h es a m eb l o t .
We found that in NonTg mice, the levels of TDP-43
and TDP-35 were similar across the three different time
points (Figure 2A-B). In contrast, our results indicated
that in the 3×Tg-AD mice the levels of TDP-43 and
TDP-35 were significantly higher at 6 months of age,
compared to 2 and 12 months of age (Figure 2C-D).
Taken together, these data indicate that the higher levels
of TDP-43 and TDP-35 in the brains of 6-month-old
3×Tg-AD mice compared to NonTg mice are due to an
increase of these proteins in the 3×Tg-AD mice as a
function of age and not to a decrease of the levels of
TDP-43 and TDP-35 in the brains of NonTg mice.
An e u r o p a t h o l o g i c a lf e a t u r eo fT D P - 4 3p r o t e i n o p a -
thies is the mislocalization of TDP-43, from its predomi-
nantly nuclear location into the cytosol, where it
accumulates [29] To determine whether there is mislo-
calization of TDP-43 and TDP-35 in the brains of the
3×Tg-AD mice, we extracted nuclear and cytosolic pro-
teins from the brains of 2-, 6-, 12-month-old 3×Tg-AD
and NonTg mice (n = 6/genotype/time-point). Using
W e s t e r nb l o ta n a l y s i s ,w ef o u n dt h a ta t2a n d1 2
months of age, the levels of TDP-43 and TDP-35 were
not statistically different between 3×Tg-AD and NonTg
mice in the nuclear and cytosolic fractions (Figure 3A-
C, G-I). In contrast, at 6 months of age, the levels of
cytosolic TDP-43 and TDP-35 were significantly higher
in the 3×Tg-AD mice compared to age- and gender-
matched NonTg mice (Figure 3D-F). Unexpectedly, we
found that the nuclear levels of TDP-43 and TDP-35
were not statistically different between NonTg and
3×Tg-AD mice (Figure 3D-F), suggesting that the
increase of the levels in the cytosolic fraction is not sim-
ply due to a redistribution of TDP-43 from the nucleus
into the cytoplasm. As expected, the levels of TDP-43
and its C-terminal fragments were constantly higher in
the nuclear fraction compared to the cytosolic fraction
(Figure 3A, D, G). Moreover, in the cytosolic fraction, at
all ages and independent of the genotype, the predomi-
nant species was TDP-35. In the nuclear fraction there
were bands with different molecular weights, indicating
more TDP-43 species. Future studies are needed to
understand the nature of these fragments.
Tau pathology is another hallmark feature of AD and
develops in the 3×Tg-AD mice as a function of age
[38,42]. In the 3×Tg-AD mice tau first accumulates in
the somatodendritic compartment, and as the mice age,
it becomes hyperphosphorylated and eventually aggre-
gates to form NFTs [38,42]. Phosphorylation at Thr181
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the earliest manifestations of tau pathology in the 3×Tg-
AD mice and occurs at 6 months of age (Figure 4A). As
the mice age, AT270 immunoreactivity increases (Figure
4A), and the age-dependent increase is also detected by
Western blot (Figure 4B-C). We next sought to deter-
mine whether there is a relation between AT270, TDP-
43 and TDP-35. We focused on the AT270 epitope
because in the 3×Tg-AD mice tau phosphorylation at
Thr181 correlates with cognitive performance (e.g.,
[43]). Linear regression analysis indicated that the levels
of AT270 in the brains of 6-month-old 3×Tg-AD mice
do not correlate with the levels of TDP-43 and TDP-35
(Figure 4D-E; r
2 = 0.09148, p = 0.56; and r
2 = 0.1491,
p = 0.45, respectively). Neither was a correlation
between AT270 and TDP-43 and TDP-35 levels
observed at 12 months of age (Figure 4F-G; r
2 = 0.4644,
p = 0.14; and r
2 = 0.4469, p = 0.15). The lack of correla-
tion between TDP-43 and tau is consistent with data
showing that TDP-43 deposits in AD brains do not co-
localize with NFTs or dystrophic neuritis [37].
Evidence indicates a primary role for Ab oligomers in
AD pathogenesis [12]. In the 3×Tg-AD mice, Ab oligo-
merization starts intraneuronally, and a strong immu-
noreactivity can be detected with the M71/3 antibody,
which is specific for low molecular weight Ab oligomers
(Figure 5A, C; [44,45]). As the mice age, however, the
intraneuronal M71/3 immunoreactivity decreases (Figure
5A-D). We have previously shown that this decrease in
M17/3 in 12-month-old 3×Tg-AD mice correlates with
the appearance of extracellular Ab plaques [44]. Next, to
further analyze the changes in Ab oligomer levels in the
brains of the 3×Tg-AD mice, we performed dot blot
experiments using A11, an oligomeric-specific antibody
that recognizes high molecular weight Ab oligomers
[46]. Consistent with the M71/3 data, we found that the
A11 levels peak at 6 months of age and decrease at
12 months of age (Figure 5E-F). To determine the rela-
tion between TDP-43, TDP-35 and Ab oligomers, we
correlated oligomeric Ab levels obtained by A11 dot
blot with TDP-43 and TDP-35 levels in 6- and
12-month-old 3×Tg-AD mice. We found that in
Figure 1 3×Tg-AD mice have higher levels of TDP-43 and TDP-35. (A) Representative Western blots of proteins from the low salt fraction
extracted from 2-month-old 3×Tg-AD and NonTg mice and probed with the indicated antibodies. A longer exposure time was necessary to see
the less abundant low molecular weight fragments. (B) Quantitative analysis of the blots shows that at 2 months of age the levels of TDP-43
and TDP-35 were similar between 3×Tg-AD and NonTg mice (n = 6/genotype). (C) Representative Western blots of proteins from the low salt
fraction extracted from 6-month-old 3×Tg-AD and NonTg mice. (D) Quantitative analysis of the blots shows that at 6 months of age the levels
of TDP-43 and TDP-35 were significantly increased (p = 0.04 and p = 0.01, respectively) in the brains of the 3×Tg-AD mice compared to age-
and gender-matched NonTg mice (n = 6/genotype). (E) Representative Western blots of proteins from the low salt fraction extracted from 12-
month-old 3×Tg-AD and NonTg mice (n = 6/genotype). (F) Quantitative analysis of the blots shows that at 12 months of age the levels of TDP-
43 and TDP-35 were similar between 3×Tg-AD and NonTg mice (n = 6/genotype). Abbreviation: exp = exposure. Data are presented as ± SEM
and analyzed by t-test analysis.
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Page 3 of 116-month-old 3×Tg-AD mice, A11-positive Ab oligomers
positively correlated with TDP-43 (r
2 = 0.9330, p =
0.001; Figure 5G) and TDP-35 (r
2 = 0.6749, p = 0.045;
Figure 5H). Similarly, we found that A11 levels in 12-
month-old 3×Tg-AD mice positively correlate with
TDP-43 (r
2 = 0.7259, p = 0.031; Figure 5I). A strong
trend was also observed when analyzing A11 and TDP-
35 levels in 12-month-old 3×Tg-AD mice (r
2 = 0.6277,
p = 0.06; Figure 5J). Taken together, these data suggest
that the increase in TDP-43 in the 3×Tg-AD mice may
be due to the increase in soluble Ab oligomers.
The strong correlation between Ab oligomers and
TDP-43 levels led us to hypothesize that the buildup of
Ab oligomers maybe the cause underlying the increase
in TDP-43 levels in the 3×Tg-AD mice. To test this
hypothesis we used a double transgenic mouse model
(referred to as APP/tau mice) that we previously gener-
ated by replacing the mutant PS1 allele with its wild
type counterpart in the 3×Tg-AD mice, thereby obtain-
ing double transgenic mice expressing APP and tau [47].
Because of the M146V mutation in the PS1 gene, the
3×Tg-AD mice accumulate 10 times more Ab42 than
Ab40 [38]. Thus, replacing the M146V mutation with its
wild type counterpart significantly decreased Ab42 levels
[47]. Here we used the APP/tau mice to determine the
effects of preventing Ab oligomers accumulation on
TDP-43 levels. At 6 month of age, the APP/tau mice
show a significant reduction in intraneuronal Ab immu-
noreactivity compared to age- and gender-matched
3×Tg-AD mice (Figure 6A, B). Notably, the APP/tau
mice did not show any M71/3 immunoreactivity (Figure
6C). To determine the effect of preventing Ab accumu-
lation on TDP-43, we measured the steady-state levels
of TDP-43 and TDP-35 in the low salt fraction of pro-
teins extracted from the brains of the APP/tau mice by
W e s t e r nb l o t( F i g u r e6 D ) .W ef o u n dt h a tt h el e v e l so f
TDP-43 and TDP-35 were significantly lower in the
brains of the APP/tau mice compared to 3×Tg-AD mice
(Figure 6E-F). Notably, the levels of TDP-43 and TDP-
35 were not significantly different between APP/tau and
NonTg mice. Taken together, the results presented here
strongly argue of a causal relation between the build-up
of Ab oligomers and the increase in TDP-43 levels.
Discussion
In addition to representing the major pathological pro-
tein that accumulates in CNS inclusions characterizing
ALS and FTLD-U, TDP-43 positive inclusions have
been found in ~30% of AD cases [34,37,39]. Specifically,
the accumulation of low molecular weight C-terminal
fragments has been reported in human AD patients
[48]. Notably, these fragments may play a primary role
in the disease pathogenesis as their expression in vitro is
sufficient to cause TDP-43 mislocalization [31-33]. The
clinical significance of TDP-43 accumulation in AD and
its relation with the two neuropathological hallmarks of
AD (Ab and tau) is not understood. In this study, we
elucidate this relation using an animal model of AD.
Our results indicate that in the brains of the 3×Tg-AD
mice the levels of full length TDP-43 and its ~35 kDa
C-terminal fragment change as a function of age and Ab
oligomer levels. Notably, we found that TDP-43 and
TDP-35 levels significantly correlated with Ab oligo-
mers, thereby suggesting a possible relation between Ab
and TDP-43. Toward this end, we found that TDP-43
and TDP-35 levels were higher in 6-month-old 3×Tg-
AD mice compared to age-matched NonTg mice, but
n o ta t1 2m o n t h so fa g e .P r e v i o u s l yw es h o w e dt h a tA b
oligomers levels in the 3×Tg-AD mice peak at 6 months
Figure 2 Age-dependent changes in TDP-43 and TDP-35 levels.
(A) Representative Western blots of proteins from the low salt
fraction extracted from 2-, 6- and 12-month-old NonTg mice and
probed with a polyclonal antibody raised against TDP-43 antibody.
A longer exposure time was necessary to see the less abundant low
molecular weight fragments. (B) Quantitative analysis of the blots
shows that the levels of TDP-43 and TDP-35 were similar across the
three different ages analyzed (n = 6/time-point). (C) Representative
Western blots of proteins from the low salt fraction extracted from
2-, 6- and 12-month-old 3×Tg-AD mice and probed with a
polyclonal antibody raised against TDP-43 antibody. (B) Quantitative
analysis of the blots shows that the levels of TDP-43 and TDP-35
were significantly higher at 6 months of age (n = 6/time-point).
Abbreviation: exp = exposure. Data are presented as ± SEM and
analyzed by one way ANOVA.
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Page 4 of 11of age and are significantly lower at 12 months of age
[44], which is consistent with the hypothesis that the
increased TDP-43 levels in 6-month-old 3×Tg-AD mice
m a yb ed u et oh i g hl e v e l so fA b oligomers. Indeed, we
show that genetically preventing Ab42 accumulation in
the 3×Tg-AD mice is sufficient to decrease TDP-43
levels, further supporting an interaction between Ab and
TDP-43.
It is widely accepted that Ab oligomers play a central
role in AD pathogenesis [17-19]. Toward this end, it has
been shown that low concentrations of Ab oligomers
can kill neurons, impair LTP, and lead to cognitive
decline [49-55]. Ab oligomers have been shown to inter-
act with several signaling transduction pathways [56-61].
Although the mechanism underlying the Ab-mediated
accumulation of TDP-43 in the 3×Tg-AD mice remains
to be elucidated, it is tempting to speculate that altera-
tions in signaling transduction pathways due to the
build-up of Ab oligomers may be responsible for
TDP-43 accumulation and misprocessing. For example,
caspase 3 and 7 can cleave TDP-43 and lead to the
accumulation of TDP-43 fragments [62]. Notably,
Figure 3 Age-dependent changes in TDP-43 and TDP-35 cellular localization. (A) Representative Western blots of proteins from the
cytosolic and nuclear fractions extracted from 2-month-old NonTg and 3×Tg-AD mice and probed with the a polyclonal anti-TDP antibody. A
longer exposure was necessary to see the less abundant low molecular weight fragments. (B-C) Quantitative analysis of the blots shows that at
2 months of age the nuclear and cytosolic levels of TDP-43 and TDP-35 were not statistically significant between 3×Tg-AD and NonTg mice (n =
6/genotype). (D) Representative Western blots of proteins from the cytosolic and nuclear fractions extracted from 6-month-old NonTg and 3×Tg-
AD mice and probed with a polyclonal anti-TDP antibody. (E-F) Quantitative analysis of the blots shows that at 6 months of age the nuclear
levels of TDP-43 and TDP-35 were not statistically significant between 3×Tg-AD and NonTg mice (n = 6/genotype). In contrast, the cytosolic
levels of TDP-43 and TDP-35 were significantly higher in the 3×Tg-AD mice compared to NonTg mice (p = 0.03 and p = 0.01, respectively). (G)
Representative Western blots of proteins from the cytosolic and nuclear fractions extracted from 12-month-old NonTg and 3×Tg-AD mice and
probed with a polyclonal anti-TDP antibody. (H-I) Quantitative analysis of the blots shows that at 12 months of age the nuclear and cytosolic
levels of TDP-43 and TDP-35 were not statistically significant between 3×Tg-AD and NonTg mice (n = 6/genotype). Abbreviation: exp =
exposure. Data are presented as ± SEM and analyzed by t-test analysis.
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AD brains [63], and, more specifically, there is evidence
that Ab oligomers can increase caspase activity [64-66].
This is consistent with data showing that TDP-43 can
be cleaved, in a caspase dependent manner, to generate
TDP-43 C-terminal fragments [62]. Thus, it is tempting
to speculate that an Ab-increase in caspase activity may
facilitate the formation of the ~35kDa C-terminal
Figure 4 TDP-43 and TDP-35 levels do not correlate with tau
phosphorylated at Thr181. (A) Representative microphotographs
of 3×Tg-AD brain sections depicting hippocampal CA1 pyramidal
neurons stained with the anti-tau antibody AT270, which recognize
tau phosphorylated at Thr181 (n = 6/age group). (B) Representative
Western blots of proteins extracted from 6- and 12-month old
3×Tg-AD mice probed with the AT270 antibody. b-actin is used as a
loading control. (C) Quantitative analysis of the blots shows that the
steady-state levels of AT270 were significantly higher in the brains
of 12-month-old 3×Tg-AD mice compared to 6-month-old mice
(n = 6/age group; p < 0.05). Data are presented as ± SEM and
analyzed by t-test analysis. (D-E) Linear regression analysis indicated
that the levels of AT270 in the brains of 6-month-old 3×Tg-AD mice
did not correlate with the levels of TDP-43 (r
2 = 0.09148, p = 0.56)
and TDP-35 (r
2 = 0.1491, p = 0.45). (F-G) Similarly, no correlation
between AT270 and TDP-43 (r
2 = 0.4644, p = 0.14) and TDP-35 (r
2 =
0.4469, p = 0.15) levels was observed at 12 months of age.
Figure 5 Ab oligomers correlate with TDP-43 and TDP-35.( A-D)
Representative microphotographs showing 3×Tg-AD hippocampal
sections stained with the antibody M71/3, which is specific for Ab
oligomers. Panels C and D show higher magnification views of
panels A and B, respectively (n = 6/age group). (E) Representative dot
blots of protein extracted from 2-, 6-, and 12-month-old 3×Tg-AD
mice and probed with the antibody A11, which is specific for Ab
oligomers. (F) Quantitative analysis of the dot blots shows that at 6
months of age, A11 levels were significantly higher compared to 2-
month-old mice (p < 0.001) and 12-month-old mice (p < 0.05). (G-H)
Linear regression analysis indicated that the levels of A11 in the
brains of 6-month-old 3×Tg-AD mice significantly correlated with the
levels of TDP-43 (r
2 = 0.9330, p = 0.001) and TDP-35 (r
2 = 0.6749,
p = 0.045). (I) Similarly, the levels of A11 in the brains of 12-month-
old 3×Tg-AD mice significantly correlated with TDP-43 (r
2 = 0.7259,
p = 0.031). (J) A strong trend was observed when analyzing A11 and
TDP-35 levels in 12-month-old 3×Tg-AD mice (r
2 = 0.6277, p = 0.06).
The dotted lines in panels G-J represent 95% confidence intervals.
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cytosolic TDP-43 levels are higher in 6-month-old
3×Tg-AD mice compared to age- and gender-matched
NonTg mice. Such an increase, however, was not due to
a redistribution of TDP-43 from the nucleus into the
cytoplasm as we found that nuclear TDP-43 levels were
similar between 3×Tg-AD and NonTg mice. It is possi-
ble that a reduction in protein turnover may account for
the higher levels of TDP-43 and TDP-35 in the 3×Tg-
AD mice. Notably, Ab oligomers have been shown to
reduce the activity of the ubiquitin-proteasome-system
and autophagy [61,67], two major protein turnover sys-
tems that are involved in TDP-43 clearance as indepen-
dently reported by several laboratories [31,68-70].
Contradicting reports have been published on the rela-
tion between TDP-43 and tau pathology. Specifically, in
brains from AD patients, more often than not, tau
immunoreactivity does not correlate with TDP-43 posi-
tive neurons [48], which is consistent with our data
showing that TDP-43 and TDP-35 levels did not
Figure 6 Reduction of Ab42 levels decreases TDP-43 and TDP-35 levels. (A-B) Representative microphotographs depicting CA1 pyramidal
neurons from 6-month-old 3×Tg-AD and APP/tau mice stained with an anti-Ab antibody (n = 6/group). (C) Representative microphotograph
depicting CA1 pyramidal neurons from APP/tau mice stained with the anti-oligomeric antibody M17/3. (D) Representative Western blots of
protein extracted from the brains of 6-month-old NonTg, APP/tau and 3×Tg-AD mice (low salt fraction), probed with a polyclonal anti-TDP-43
antibody. b-Actin is used as a loading control. A longer exposure time was necessary to see the less abundant low molecular weight fragments.
(E-F) Quantitative analysis of the blots (n = 6/genotype) shows that in APP/tau mice, the steady-state levels of TDP-43 and TDP-35 are
significantly lower in APP/tau mice compared to 3×Tg-AD mice (p < 0.05). The levels of TDP-43 and TDP-35 were not statistically significant
different between APP/tau and NonTg mice. Data are presented as means ± SEM and were analyzed using one-way ANOVA following by post
hoc Bonferroni test to determine individual differences in groups. Abbreviation: exp = exposure.
Caccamo et al. Molecular Neurodegeneration 2010, 5:51
http://www.molecularneurodegeneration.com/content/5/1/51
Page 7 of 11correlate with phosphorylated tau at Thr181. However,
it has been reported that the Braak score for neurofibril-
lary tau pathology is higher in AD cases with TDP-43
immunoreactivity [48]. To complicate this apparent con-
tradiction are the data showing that in dementia with
Lewy bodies, a disease also characterized by tau accu-
mulation, TDP-43 immunoreactivity is not related with
Braak neurofibrillary tau pathology [48]. Although we
found that in the 3×Tg-AD mice, TDP-43 levels did not
correlate with tau phosphorylated at Thr181, further
studies are needed to establish whether TDP-43 levels
will change in relation to NFT, as suggested by some
studies with human brains [34,48], or with total tau
levels. Specifically, the latter could not be addressed
using the 3×Tg-AD mice, where the tau transgene does
not change as a function of age and its steady-state level
reflect the promoter activity. Thus any attempt of corre-
lating total tau to TDP-43 would have been artificial.
Furthermore, a report by Amador-Ortiz and colleagues
shows that in some selective regions of AD brains,
TDP-43 deposits correlate with phosphotau, whereas in
other regions within the same brain, no correlation was
found [34]. This apparent discrepancy could arise from
the sample preparation; indeed, the data presented here
from the 3×Tg-AD mice where obtained from whole
brain homogenize and compare the levels of soluble tau
and soluble TDP-43 and TDP-35. Finally, the relation-
ship between other phosphotau epitopes and TDP-43
remains to be determined.
Conclusions
The data presented here provide compelling evidence
that in the brain of the 3×Tg-AD mice, the accumula-
tion of soluble Ab oligomers may be responsible for the
increase in the steady-state levels of TDP-43 and TDP-
35. It should be noted, however, that the biochemical
profile of TDP-43 detected in the 3×Tg-AD mice was
different from that believed pathogenic in FTLD-U [29],
suggesting that in these mice changes in TDP-43 levels
do not play a role in the AD-like phenotype developed
by these mice. Further studies will be needed to eluci-
date whether TDP-43 plays a clinical role in AD
pathogenesis.
Materials and methods
Mice
The generation of the 3×Tg-AD and APP/tau mice was
previously described [38,47]. Briefly, the 3×Tg-AD mice
were generated by co-injecting two different transgenes
encoding human APPswe and human tau P301L, both
under the control of the Thy1.2 promoter, into single-
cell embryos harvested from homozygous mutant
PS1M146V knock-in mice (PS1-KI). The APP/tau mice
were generated crossing homozygous 3×Tg-AD mice
with NonTg mice to replace the mutant PS1 allele with
its wild type counterpart.
Immunohistochemistry
Mice were sacrificed by CO2 asphyxiation and their
brains rapidly removed and dropped fixed for 48 hours
in 4% paraformaldehyde. Free-floating sections (50 μm
thick) were obtained using a vibratome slicing system
(Leica VT1200S, Germany) and stored in 0.02% sodium
azide in PBS. Following two washes with TBS, endogen-
ous peroxidase activity was quenched for 30 minutes in
3% H2O2. For epitope exposure sections were next incu-
bated in 90% formic acid for 7 minutes, followed by tree
additional washes in TBS (100 mM Tris pH 7.5; 150
mM NaCl). The proper primary antibody was applied
overnight at 4°C. Sections were washed 3 times in TBS
and then incubated with the suitable secondary antibody
for 1 hour at room temperature. Sections were then
developed with diaminobenzidine (DAB) substrate using
the avidin-biotin horseradish peroxidase system (Vector
Labs, Burlingame, CA).
Protein extraction
Following CO2 asphyxiation, brains were extracted and
frozen in dry ice. To obtain the low and high salt
fractions, brains were homogenized with a power homo-
genizer in 1 ml of low salt buffer (10 mM Tris pH7.5,
5 mM EDTA, 1 mM DTT, 10% Sucrose) in the presence
of protease inhibitors. Samples were then centrifuged at
14,400 rpm for 30 minutes at 4°C. The supernatant was
stored at -80°C as low salt fraction. To obtain the cyto-
solic and nuclear fractions, brains were washed in PBS
and then homogenized with a dounce homogenizer with
2 ml of solution A (10 mM Hepes pH7.9, 10 mM KCL,
0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT) in the pre-
sence of protease inhibitors. After 5 initial strokes, 0.5%
of NP40 was added, and the brain was further homoge-
nized with 5 additional strokes. Subsequently, the solu-
tion was kept in ice for 10 minutes and centrifuged 1
minute at 11,000 rpm. The supernatant was removed
and stored at -80°C as cytosolic fraction. The pellet was
re-suspended in 250 μlo fS o l u t i o nB( 2 0m MH e p e s
pH7.9, 400 mM Nacl, 1 mM EDTA, 1 mM EGTA, 1
mM DTT) in the presence of protease inhibitors and
placed in ice for 15 minutes. Finally, the tubes were cen-
trifuged 5 minutes at 11,000 rpm and the supernatant
was stored at -80°C as nuclear fraction.
Western blot and dot blot
Proteins were resolved using precast SDS/PAGE gels
(Invitrogen, Carlsbad, CA) under reducing conditions
and transferred to a nitrocellulose membrane. The
membrane was incubated in a 5% solution of non-fat
dry milk in T-TBS (0.02% Tween 20, 100 mM Tris pH
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Page 8 of 117.5; 150 nM NaCl) for 1 hour at 20°C. The membrane
was then incubated in the proper primary antibody at
4°C overnight. The blots were washed in T-TBS for
20 minutes and incubated at 20°C with the appropriate
secondary antibody for 1 hour. After a final 20-minute
wash in T-TBS, blots were developed for 5 minutes with
Super Signal (Pierce, Rockford, IL), washed and exposed.
For dot-blots, proteins were applied in a nitrocellulose
membrane and air dried. Membranes were resolved as
described above.
Antibodies
The following antibodies were used in this study: AT270
(Pierce, Rockford, IL) anti-b-actin (Sigma, St. Louis,
MO), rabbit anti human TARDBP polyclonal antibody
(ProteinTech Group, Chicago, IL), A11 (a gift from Dr.
Charles Glabe, University of California, Irvine), M71/3
(a gift from Dr. William Klein, Northwestern University,
Evanston, IL).
Statistical evaluation
T h ed a t aw e r es u b s e q u e n t l ya n a l y z e db yA N O V Ao rt -
test comparison as detailed in the figure legends, using
Graphpad Prism software (Graphpad Prism Inc., San
Diego, CA).
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